Literature DB >> 10098988

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

V Soriano1, J García-Samaniego, E Valencia, R Rodríguez-Rosado, F Muñoz, J González-Lahoz.   

Abstract

The life expectancy of HIV-positive individuals has been prolonged in recent years, as a consequence of the wide use of antiretroviral drugs and primary prophylaxis for the most common opportunistic infections. In HIV-positive persons infected parenterally, chronic viral liver disease (CVLD), mainly that caused by hepatitis C virus (HCV), is frequently seen. Moreover, chronic hepatitis C seems to present a more accelerated course in HIV-infected patients, leading to cirrhosis and liver failure in a shorter period of time. The aim of the present study was to investigate the impact of CVLD on the morbidity and mortality of HIV-positive patients. A retrospective analysis of the causes of hospital admission during a 4.5-year period in a reference centre for AIDS situated in Madrid was performed. Decompensated liver disease (encephalopathy, ascites, jaundice), or complications directly related to it (gastrointestinal bleeding, hepatorenal syndrome, peritonitis) were diagnosed in 143 (8.6%) of 1670 hospital admissions. These episodes of CVLD corresponded to 105 different individuals, a quarter of whom had two or more re-admissions. HCV alone or in combination with other hepatotropic viruses was involved in 93 (88.6%) patients admitted for CVLD. Death directly associated with CVLD occurred in 15 individuals, which represented 4.8% of the total causes of inhospital mortality during the study period, and represented the fifth cause of death in hospital for HIV-infected patients. In conclusion, CVLD represents an important cause of hospital admission and death in HIV-infected drug users.

Entities:  

Mesh:

Year:  1999        PMID: 10098988     DOI: 10.1023/a:1007506617734

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  19 in total

1.  Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

Authors:  A Sánchez-Quijano; J Andreu; F Gavilán; F Luque; M A Abad; B Soto; J Muñoz; J M Aznar; M Leal; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

2.  Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group.

Authors:  V Soriano; J García-Samaniego; R Bravo; J González; A Castro; J Castilla; P Martínez-Odriozola; M Colmenero; E Carballo; D Suárez; F J Rodríguez-Piñero; A Moreno; J del Romero; J Pedreira; J González-Lahoz
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

3.  Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.

Authors:  B Soto; A Sánchez-Quijano; L Rodrigo; J A del Olmo; M García-Bengoechea; J Hernández-Quero; C Rey; M A Abad; M Rodríguez; M Sales Gilabert; F González; P Mirón; A Caruz; F Relimpio; R Torronteras; M Leal; E Lissen
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

4.  More severe course of delta hepatitis in HIV-infected patients [L].

Authors:  M de Pouplana; V Soriano; J G Samaniego; A Enríquez; F Muñoz; J González-Lahoz
Journal:  Genitourin Med       Date:  1995-04

5.  Morbidity and mortality from transfusion-transmitted disease in haemophilia.

Authors:  C A Lee; C A Sabin; A N Phillips; J Elford; J Pasi
Journal:  Lancet       Date:  1995-05-20       Impact factor: 79.321

6.  The progression of HCV-associated liver disease in a cohort of haemophilic patients.

Authors:  P Telfer; C Sabin; H Devereux; F Scott; G Dusheiko; C Lee
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

7.  Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation Group.

Authors:  S Vella; M Giuliano; P Pezzotti; M G Agresti; C Tomino; M Floridia; D Greco; M Moroni; G Visco; F Milazzo
Journal:  JAMA       Date:  1992-03-04       Impact factor: 56.272

8.  [Changes in the spectrum of the diseases in patients hospitalized with HIV infection].

Authors:  V Soriano; E Valencia; A Alba; F Laguna; V Moreno; J C Alberdi; J García-Samaniego; J González-Lahoz
Journal:  Med Clin (Barc)       Date:  1993-12-04       Impact factor: 1.725

9.  Use of CD4 lymphocyte count to predict long-term survival free of AIDS after HIV infection.

Authors:  A N Phillips; C A Sabin; J Elford; M Bofill; G Janossy; C A Lee
Journal:  BMJ       Date:  1994-07-30

10.  [Morbidity and mortality associated with chronic viral hepatopathy in patients infected with the human immunodeficiency virus].

Authors:  V Soriano; J García-Samaniego; R Bravo; E Valencia; F Laguna; M de Pouplana; A Iñíguez; F Muñoz; J González-Lahoz
Journal:  Med Clin (Barc)       Date:  1995-05-06       Impact factor: 1.725

View more
  23 in total

1.  Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.

Authors:  Camilla S Graham; Annalee Wells; Tun Liu; Kenneth E Sherman; Marion Peters; Raymond T Chung; Atul K Bhan; Janet Andersen; Margaret James Koziel
Journal:  AIDS       Date:  2006-02-14       Impact factor: 4.177

2.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

3.  Serum Adenosine Deaminase (ADA) Activity: A Novel Screening Test to Differentiate HIV Monoinfection From HIV-HBV and HIV-HCV Coinfections.

Authors:  Mohammad Abdi; Rizgar Rahbari; Zahed Khatooni; Nima Naseri; Adel Najafi; Iraj Khodadadi
Journal:  J Clin Lab Anal       Date:  2015-02-16       Impact factor: 2.352

4.  Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a case-control study.

Authors:  E Shaw; J Castellote; M Santín; X Xiol; G Euba; C Gudiol; C Lopez; X Ariza; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-05       Impact factor: 3.267

5.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 6.  Hepatitis C virus infection in children coinfected with HIV: epidemiology and management.

Authors:  Massimo Resti; Chiara Azzari; Flavia Bortolotti
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

Review 8.  Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations.

Authors:  Miriam Romero; Mayte Pérez-Olmeda; Javier García-Samaniego; Vicente Soriano
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 9.  Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

Authors:  Vincent Lo Re; Jay R Kostman; Valerianna K Amorosa
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

Review 10.  Underlying pathophysiology of HCV infection in HIV-positive drug users.

Authors:  Anuradha Balasubramanian; Jerome E Groopman; Ramesh K Ganju
Journal:  J Addict Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.